Corona Remedies opened higher at ₹2,350.80, compared with its previous close of ₹2,342.20. In the last trading session on 13 Nov 2026, the stock traded between ₹2,318.00 and ₹2,391.90, with an average traded price of ₹2,345.96. It showed a sideways intraday trend.
An investment of ₹10,000 made 1 year ago in Corona Remedies is now worth
₹ 16,196.00
Giving a profit of
₹ 6,196.00 (61.96%)
Note: Past profits do not guarantee future returns.
Rating by Refinitive from 2 Analysts
Today's Change
-12.50 (-0.53%)
Day High
₹2,391.90
Day Low
₹2,318.00
Day Open
₹2,350.80
Prev Close
₹2,342.20
Volume
25,789
Value Traded
₹6.05 Cr
1W Return
-2.11%
1M Return
15.60%
3M Return
9.07%
6M Return
42.82%
1Y Return
61.96%
Market Cap (₹ Cr.)
14,248
PE Ratio
69.20
PB Ratio
17.81
Dividend Yield
0.43%
ROE
24.79%
ROCE
29.31%
Book Value (₹)
131.64
Face Value (₹)
10.00
EPS (TTM)
9.86
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-2.11%
6 Weeks
-
1 Month
15.60%
3 Months
9.07%
9 Months
44.33%
Corona Remedies to hold London, UAE meets; adds Mumbai conference
Corona Remedies to hold investor meetings in London and UAE from Nov 4-6, 2026. Added participation in Avendus Spark conference in Mumbai on Nov 16, 2026. All discussions restricted to publicly available information, no UPSI shared.
7 days agoCorona Remedies receives ₹4.88 crore demand notice from NPPA
Corona Remedies received a demand notice of ₹4,87,97,160 from NPPA. The notice alleges violation of Para 15 of DPCO 2013 regarding price approvals. Company states the demand includes interest and penalty components. Corona Remedies asserts no material financial impact from the notice.
11 days agoCorona Remedies Q2FY27 Results: Revenue up 22% YoY to ₹441 crore
Revenue from operations rose 22.2% YoY to ₹441.17 crore in Q2FY27. Net profit after tax increased 15.3% YoY to ₹60.18 crore. Audio recording of the Q2FY27 earnings conference call is now available on the company website.
12 days agoCorona Remedies secures ANVISA GMP certification for Brazilian exports
Secured ANVISA GMP certification for OSD and hormone facilities in Ahmedabad. Third major international GMP accreditation, adding to EU and EAEU approvals. Brazil market estimated at $44 billion, offering significant export potential. India remains primary market, contributing over 96% of total revenue.
23 days agoSepia, Sage, Anchor sell 2.63m Corona Remedies shares under SAST
Sepia Investments, Sage Investment Trust, and Anchor Partners sold 2.63 million shares. Sales occurred via open market on NSE on September 10, 2026. Disclosure filed under SEBI SAST Regulations 29(2). Sepia's stake reduced from 12.68% to 8.62%. Sellers are identified as persons acting in concert.
1mo agoCorona Remedies to host JP Morgan-led analyst meet on Sep 23
Corona Remedies to hold analyst meet on Sep 23, 2026. Session organized by JP Morgan in Ahmedabad at 2:00 pm. Discussions limited to publicly available information. No unpublished price-sensitive information to be shared.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,880.00 | -0.27% | ₹4,51,074.97 | 41.20 | +8.54% | |
| ₹11,442.00 | -0.37% | ₹3,03,749.15 | 90.40 | +75.49% | |
| ₹4,670.00 | -1.21% | ₹1,77,631.79 | 85.50 | +22.10% | |
| ₹2,424.00 | +1.00% | ₹1,30,971.68 | 97.10 | +145.03% | |
| ₹1,189.90 | -1.33% | ₹1,18,692.98 | 28.00 | +25.07% | |
| ₹1,380.00 | -0.48% | ₹1,15,185.88 | 42.00 | +12.23% | |
| ₹1,391.80 | -1.17% | ₹1,12,437.74 | 39.90 | -8.39% | |
| ₹2,640.00 | +0.05% | ₹1,09,043.90 | 48.10 | +16.30% | |
| ₹1,823.20 | +0.89% | ₹1,04,902.90 | 26.00 | +54.04% | |
| ₹1,980.30 | -1.72% | ₹90,557.13 | 17.60 | -2.64% | |
| ₹2,640.00 | -0.74% | ₹74,507.31 | 51.60 | +42.87% | |
| ₹5,114.00 | -3.55% | ₹61,145.54 | 30.50 | -11.33% |
An investment of ₹10,000 made 1 year ago in Corona Remedies is now worth
₹ 16,196.00
Giving a profit of
₹ 6,196.00 (61.96%)
Note: Past profits do not guarantee future returns.